|
 Qualifications of the Investigators.
BIOGRAPHICAL SKETCH
Provide the following information for the Principal Investigator and other key personnel
NAME: Amrollah Ahmadi
POSITION TITLE: Researcher
EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as chemistry, and include postdoctoral training.) |
|
Read more...
|
| Title |
The effect of HESA-A on psoriasis vulgaris. |
| Author(s) |
Ahmadi A, Barikbin B, Naseri M, Mohagheghi M |
| Institution |
Cancer Institute Research Center, Tehran University of Medical Sciences, Tehran, Iran.
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
|
| Source |
J Drugs Dermatol 2008 Jun; 7(6):559-61. |
| Abstract |
BACKGROUND: Psoriasis vulgaris is one of the most common chronic skin disorders without any curative treatment. The aim of this study was to investigate the efficacy and safety of HESA-A in the treatment of psoriasis.
METHODS: In a randomized, double-blind clinical trial, 28 patients (11 male, 17 female) with chronic plaque-type psoriasis were randomly assigned to treatment and placebo groups. Patients in treatment group received HESA-A tablet 25 mg/kg twice a day orally and control group received placebo with the same method for 6 months and were followed clinically during the study.
RESULTS: At the end of study, in the treatment group psoriatic plaques were absent (no evidence of psoriasis or complete remission) in 9 cases (64.2%) and was very mild (controlled, but not entirely cleared) in 5 cases (35.8%). Disease relief was observed in 10 (71.4%) patients after 4 months, in 2 cases (14.3%) after 5 months and in 2 (14.3%) other patients after 6 months while none of the controls showed disease improvement.
CONCLUSION: This study showed rapid and good efficacy and safety of HESA-A in the treatment of plaque-type psoriasis. |
| Language |
eng |
| Pub Type(s) |
Journal Article |
| PubMed ID |
18561587 |
|
|
TOXICOLOGICAL STUDIES ON AN ANTICANCER DRUG (HESA-A) WITH MARINE ORIGIN
|
|
Read more...
|
|
DARU
2003;11(3) : 82-87
Cytotoxicity and Antitumor Properties of a Marine Compound , HESA-A , on Cancer Cells.
Hojjat Sadeghi- Aliabadi , Amrollah Ahmadi
| |
| Abstract: |
| Majority of the currently available anticancer drugs are designed to have selective toxicity to rapidly dividing cells. Among these agents the focus of many studies are compounds obtained from natural products with high therapeutic index. In this study the cytotoxicity of HESA-A, a marine compound, on cancer and normal cells was evaluated. HESA-A was prepared in normal saline as a stock solution (0.8 mg/ml, pH=7.4), sterilized and further diluted to final concentrations of 0.4, 0.2, 0.1 and 0.05 mg/ml. Cells (MDA-MB-468, Hep-2, Hela as cancer cells; L929 and McCoy as normal cells) were grown in completed RPMI 1640 and seeded in 96 well micro plates at a concentration of 1-5 ´ 104 cells/ml. After incubation for 24 h, different concentrations of HESA-A were added and cells were further incubated for 72 h. Using MTT assay, percent cell survival was determined by ELISA at 540 nm. Doxorubicin was used as a positive control (20 mg /ml). HESA-A (0.4 mg/ml) reduced the number of viable MDA-MB-468 and Hela cells to less than 50%. For Hep-2 cells the IC50 was 0.8 mg/ml. In normal cells IC50 could not be obtained at any given concentrations. These results suggest that HESA-A in therapeutic doses and in a concentration dependent manner inhibits the growth of cancer cells more selectively than normal cells. |
|
|
|
| |
|
|
|
|
